Arcturus Therapeutics - ARCT Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $64.86
Forecasted Upside: 117.79%
Number of Analysts: 7
Breakdown:
0 Sell Ratings
0 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$29.78 As of 05/17/2024 01:00 AM ET

▼ -0.72 (-2.36%)

1 month | 3 months | 12 months

Get New Arcturus Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ARCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARCT

^$64.86

▲ +117.79% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $64.86, with a high forecast of $90.00 and a low forecast of $45.00. The average price target represents a 117.79% upside from the last price of $29.78.

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Arcturus Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/26/2022

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/24/2023

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/25/2023

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/23/2023

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/21/2023

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/19/2024

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/19/2024

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/19/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/10/2024	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$87.00 ➝ $86.00	Low
3/20/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$60.00	Low
3/8/2024	William Blair	Reiterated Rating	Outperform		Low
2/8/2024	Citigroup	Boost Target	Buy ➝ Buy	$40.00 ➝ $48.00	Low
12/13/2023	Canaccord Genuity Group	Initiated Coverage	Buy		Low
12/13/2023	Canaccord Genuity Group	Initiated Coverage	Buy	$90.00	Low
11/28/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$51.00	Low
11/15/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$51.00	Low
11/15/2023	William Blair	Reiterated Rating	Outperform		Low
11/6/2023	William Blair	Reiterated Rating	Outperform		Low
9/27/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$51.00	Low
9/20/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$51.00	Low
9/5/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$51.00	Low
8/22/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$54.00	Low
8/15/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$51.00	Low
8/8/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$51.00	Low
7/24/2023	William Blair	Initiated Coverage	Outperform	$71.00	Low
7/17/2023	Wells Fargo & Company	Boost Target		$35.00 ➝ $45.00	Low
7/14/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$51.00	Low
7/14/2023	Guggenheim	Reiterated Rating	Buy		Low
7/14/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$54.00	Low
5/15/2023	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
5/11/2023	HC Wainwright	Upgrade	Neutral ➝ Buy	$19.00 ➝ $51.00	Low
3/29/2023	HC Wainwright	Reiterated Rating	Neutral	$19.00	Low
3/29/2023	Guggenheim	Reiterated Rating	Buy	$36.00	Low
11/14/2022	Wells Fargo & Company	Initiated Coverage	Overweight	$35.00	Low
11/10/2022	The Goldman Sachs Group	Boost Target	Sell	$8.00 ➝ $14.00	Low
11/10/2022	Robert W. Baird	Downgrade	Neutral ➝ Underperform	$18.00	Low
11/3/2022	Citigroup	Upgrade	Neutral ➝ Buy	$22.00 ➝ $35.00	Low
11/2/2022	Barclays	Upgrade	Underweight ➝ Equal Weight	$16.00 ➝ $25.00	Low
11/2/2022	Cantor Fitzgerald	Boost Target	Overweight	$39.00 ➝ $44.00	Low
8/10/2022	Brookline Capital Management	Reiterated Rating	Buy		Low
8/10/2022	Wells Fargo & Company	Lower Target	Overweight	$105.00 ➝ $98.00	Low
8/10/2022	Barclays	Lower Target	Underweight	$17.00 ➝ $16.00	Low
8/10/2022	Raymond James	Downgrade	Market Perform ➝ Underperform		Low
5/24/2022	The Goldman Sachs Group	Lower Target	Sell	$14.00 ➝ $8.00	High
5/11/2022	Guggenheim	Lower Target		$83.00 ➝ $36.00	High
5/11/2022	Robert W. Baird	Upgrade	Underperform ➝ Neutral	$21.00 ➝ $18.00	High
5/10/2022	Barclays	Lower Target		$21.00 ➝ $17.00	High
5/10/2022	HC Wainwright	Lower Target		$25.00 ➝ $19.00	High
5/9/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		High
4/21/2022	Citigroup	Downgrade	Buy ➝ Neutral	$86.00 ➝ $29.00	High
3/25/2022	Wells Fargo & Company	Lower Target	Overweight	$107.00 ➝ $105.00	Medium
3/15/2022	Citigroup	Lower Target	Buy	$114.00 ➝ $86.00	Low
3/1/2022	HC Wainwright	Lower Target		$47.00 ➝ $25.00	High
3/1/2022	Wells Fargo & Company	Lower Target	Overweight	$118.00 ➝ $107.00	Low
3/1/2022	Cantor Fitzgerald	Lower Target		$93.00 ➝ $86.00	Low
3/1/2022	Barclays	Lower Target		$31.00 ➝ $21.00	Low
1/31/2022	Raymond James	Upgrade	Underperform ➝ Market Perform		High
1/26/2022	HC Wainwright	Lower Target		$47.00 ➝ $33.00	High
11/16/2021	Cantor Fitzgerald	Boost Target	Overweight	$85.00 ➝ $93.00	Low
11/9/2021	Barclays	Lower Target	Positive ➝ Underweight	$46.00 ➝ $31.00	High
8/25/2021	Citigroup	Lower Target	Buy	$118.00 ➝ $114.00	High
8/12/2021	Raymond James	Downgrade	Market Perform ➝ Underperform		High
8/10/2021	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$29.00	High
8/10/2021	Cantor Fitzgerald	Boost Target	Overweight	$71.00 ➝ $85.00	High
8/10/2021	Robert W. Baird	Downgrade	Neutral ➝ Underperform	$31.00	High
7/2/2021	Cantor Fitzgerald	Initiated Coverage	Overweight	$71.00	High
6/24/2021	The Goldman Sachs Group	Initiated Coverage	Neutral	$29.00 ➝ $34.00	Low
6/21/2021	Barclays	Downgrade	Equal Weight ➝ Underweight	$33.00 ➝ $25.00	High
5/12/2021	B. Riley	Reiterated Rating	Sell	$35.00 ➝ $23.00	Low
5/11/2021	Barclays	Lower Target	Equal Weight	$46.00 ➝ $33.00	High
3/8/2021	B. Riley	Lower Target	Positive ➝ Sell	$45.00 ➝ $35.00	Low
3/2/2021	Roth Capital	Lower Target	Sell	$77.00 ➝ $45.00	Low
2/17/2021	B. Riley	Downgrade	Neutral ➝ Sell		Low
1/15/2021	B. Riley	Downgrade	Buy ➝ Neutral	$138.00 ➝ $77.00	Medium
1/7/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$118.00	N/A
12/29/2020	HC Wainwright	Downgrade	Buy ➝ Neutral	$84.00 ➝ $50.00	N/A
12/29/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$79.00 ➝ $69.00	N/A
12/29/2020	Barclays	Downgrade	Overweight ➝ Equal Weight	$68.00 ➝ $46.00	N/A
12/29/2020	Raymond James	Downgrade	Outperform ➝ Market Perform	$46.00	N/A
12/23/2020	Roth Capital	Downgrade	Buy ➝ Sell	$77.00	N/A
12/14/2020	Smith Barney Citigroup	Boost Target		$62.00 ➝ $133.00	Medium
12/7/2020	B. Riley	Boost Target	Buy	$64.00 ➝ $111.00	High
11/11/2020	B. Riley	Lower Target	Buy	$82.00 ➝ $64.00	High
11/10/2020	Raymond James	Lower Target	Outperform	$79.00 ➝ $73.00	High
10/26/2020	Barclays	Initiated Coverage	Overweight	$72.00	Medium
10/6/2020	Citigroup	Initiated Coverage	Buy ➝ Buy	$65.00	High
8/25/2020	Piper Sandler	Initiated Coverage	Overweight	$77.00	Medium
8/12/2020	B. Riley	Boost Target		$70.00 ➝ $82.00	Medium
8/11/2020	Brookline Capital Management	Reiterated Rating	Buy		Low
8/11/2020	Raymond James	Boost Target	Outperform	$72.00 ➝ $79.00	High
8/11/2020	HC Wainwright	Reiterated Rating	Buy	$78.00	High
7/30/2020	Roth Capital	Initiated Coverage	Buy	$77.00	Medium
7/24/2020	Raymond James	Reiterated Rating	Buy		High
7/24/2020	HC Wainwright	Boost Target	Buy	$62.00 ➝ $78.00	High
7/16/2020	Raymond James	Initiated Coverage	Outperform	$72.00	Medium
7/12/2020	B. Riley	Initiated Coverage	Buy	$70.00	High
6/9/2020	WBB Securities	Downgrade	Buy ➝ Hold	$31.00	Low
5/4/2020	HC Wainwright	Reiterated Rating	Buy	$62.00	Low
4/28/2020	HC Wainwright	Boost Target	Buy	$26.00 ➝ $62.00	High
4/14/2020	HC Wainwright	Boost Target	Buy	$24.00 ➝ $26.00	High
3/18/2020	Robert W. Baird	Reiterated Rating	Buy	$26.00	High
3/12/2020	HC Wainwright	Boost Target	Buy	$18.00 ➝ $24.00	High
3/5/2020	LADENBURG THALM/SH SH	Boost Target		$22.00 ➝ $28.00	High
3/4/2020	HC Wainwright	Reiterated Rating	Buy	$18.00	High
3/4/2020	Roth Capital	Boost Target	Buy	$14.00 ➝ $24.00	High
2/10/2020	Robert W. Baird	Initiated Coverage	Outperform	$24.00	High
2/6/2020	Guggenheim	Initiated Coverage	Buy	$19.00	High
1/9/2020	HC Wainwright	Reiterated Rating	Buy	$18.00	Low
8/16/2019	HC Wainwright	Set Target	Buy	$18.00	High
8/7/2019	HC Wainwright	Boost Target	Buy	$16.00 ➝ $18.00	Medium
7/24/2019	Brookline Capital Management	Reiterated Rating	Buy		High
6/20/2019	Chardan Capital	Set Target	Buy	$18.00	High

(Data available from 5/19/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

5 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/22/2023

6 very positive mentions
9 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/21/2023

7 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/21/2023

4 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/20/2024

6 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/19/2024

13 very positive mentions
23 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

3/20/2024

9 very positive mentions
11 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/19/2024

9 very positive mentions
15 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

5/19/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Today's Range

Now: $29.78

$29.58

$30.59

50 Day Range

MA: $30.63

$25.57

$38.69

52 Week Range

Now: $29.78

$17.52

$43.81

Volume

354,617 shs

Average Volume

472,377 shs

Market Capitalization

$801.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcturus Therapeutics?: The following Wall Street research analysts have issued research reports on Arcturus Therapeutics in the last twelve months: Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, StockNews.com, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for ARCT.
What is the current price target for Arcturus Therapeutics?: 7 Wall Street analysts have set twelve-month price targets for Arcturus Therapeutics in the last year. Their average twelve-month price target is $64.86, suggesting a possible upside of 117.8%. Canaccord Genuity Group Inc. has the highest price target set, predicting ARCT will reach $90.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $45.00 for Arcturus Therapeutics in the next year.
View the latest price targets for ARCT.
What is the current consensus analyst rating for Arcturus Therapeutics?: Arcturus Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARCT will outperform the market and that investors should add to their positions of Arcturus Therapeutics.
View the latest ratings for ARCT.
What other companies compete with Arcturus Therapeutics?: Other companies that are similar to Arcturus Therapeutics include Evolus, Longboard Pharmaceuticals, ALX Oncology, Tango Therapeutics and Disc Medicine. Learn More about companies similar to Arcturus Therapeutics.
How do I contact Arcturus Therapeutics' investor relations team?: Arcturus Therapeutics' physical mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 900-2660 and its investor relations email address is [email protected]. The official website for Arcturus Therapeutics is www.arcturusrx.com. Learn More about contacing Arcturus Therapeutics investor relations.

Arcturus Therapeutics - ARCT Stock Price Target and Predictions

Analyst Price Target for ARCT

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.66 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcturus Therapeutics?

What is the current price target for Arcturus Therapeutics?

What is the current consensus analyst rating for Arcturus Therapeutics?

What other companies compete with Arcturus Therapeutics?

How do I contact Arcturus Therapeutics' investor relations team?